.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Deloitte
Federal Trade Commission
Medtronic
Queensland Health
Healthtrust
Chubb
Cerilliant
Colorcon
Citi

Generated: September 25, 2017

DrugPatentWatch Database Preview

ASACOL Drug Profile

« Back to Dashboard

Which patents cover Asacol, and when can generic versions of Asacol launch?

Asacol is a drug marketed by Apil and is included in two NDAs. There are three patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in ASACOL is mesalamine. There are twenty-seven drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

Summary for Tradename: ASACOL

Patents:0
Applicants:1
NDAs:2
Suppliers / Packagers: see list5
Bulk Api Vendors: see list113
Clinical Trials: see list31
Patent Applications: see list5,868
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ASACOL at DailyMed

Pharmacology for Tradename: ASACOL

Ingredient-typeAminosalicylic Acids
Drug ClassAminosalicylate
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apil
ASACOL
mesalamine
TABLET, DELAYED RELEASE;ORAL019651-001Jan 31, 1992DISCNNoNo► Subscribe► Subscribe► Subscribe
Apil
ASACOL HD
mesalamine
TABLET, DELAYED RELEASE;ORAL021830-001May 29, 2008ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Apil
ASACOL HD
mesalamine
TABLET, DELAYED RELEASE;ORAL021830-001May 29, 2008ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Apil
ASACOL HD
mesalamine
TABLET, DELAYED RELEASE;ORAL021830-001May 29, 2008ABRXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ASACOL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apil
ASACOL
mesalamine
TABLET, DELAYED RELEASE;ORAL019651-001Jan 31, 1992► Subscribe► Subscribe
Apil
ASACOL
mesalamine
TABLET, DELAYED RELEASE;ORAL019651-001Jan 31, 1992► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for ASACOL

Drugname Dosage Strength RLD Submissiondate
mesalamineDelayed-release Tablets800 mgAsacol HD7/13/2011
mesalamineDelayed-release Tablets400 mgAsacol6/22/2007
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
US Department of Justice
Julphar
Chubb
US Army
Queensland Health
Citi
Argus Health
Colorcon
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot